Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.30 USD
Change Today -0.0268 / -8.22%
Volume 3.8M
CYTX On Other Exchanges
As of 8:10 PM 08/27/15 All times are local (Market data is delayed by at least 15 minutes).

cytori therapeutics inc (CYTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/15 - $1.47
52 Week Low
08/27/15 - $0.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

cytori therapeutics inc (CYTX) Related Bloomberg News

View More Bloomberg News

cytori therapeutics inc (CYTX) Related Businessweek News

View More BusinessWeek News

cytori therapeutics inc (CYTX) Details

Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy consisting of a heterogeneous population of specialized cells, including stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury. It also offers Celution System devices and consumable sets, and other ancillary products for the customers developing new therapeutic applications for Cytori Cell Therapy in Europe, Japan, and other regions. The company markets its products to hospitals, clinics, tissue banks, and stem cell banking companies through direct sales representatives, distributors, and partners worldwide. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

78 Employees
Last Reported Date: 03/16/15
Founded in 1996

cytori therapeutics inc (CYTX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $437.4K
Chief Financial Officer, Interim Principal Ac...
Total Annual Compensation: $79.1K
President of Asia Pacific
Total Annual Compensation: $367.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2014.

cytori therapeutics inc (CYTX) Key Developments

Cytori Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Cytori Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported product revenues of USD 1,614,000 compared to USD 935,000 a year ago. Operating profit was USD 5,792,000 compared to operating loss of USD 10,685,000 a year ago. Net income allocable to common stock holders was USD 4,450,000 compared to net loss of USD 11,828,000 a year ago. Basic and diluted earnings per share was USD 0.03 compared to USD 0.15 basic and diluted loss per share a year ago. The company continued to reduce its operating cash burn, spending approximately USD 4.8 million in the second quarter 2015, compared to USD 9.2 million in second quarter 2014. For six months, the company reported product revenues of USD 2,516,000 compared to USD 1,965,000 a year ago. Operating loss was USD 15,206,000 compared to USD 20,232,000 a year ago. Net loss allocable to common stock holders was USD 18,170,000 compared to USD 22,228,000 a year ago. Basic and diluted loss per share was USD 0.15 compared to USD 0.29 a year ago. Net cash used in operating activities was USD 9,788,000 against USD 18,137,000 a year ago. Purchases of property and equipment was USD 497,000 against USD 467,000 a year ago. Operating cash burn of USD 9.8 million compared to USD 18.1 million for the same periods in 2014.

Cytori Therapeutics Announces Launch of its U.S. Phase III/Pivotal Trial to Study Efficacy of ECCS-50 Cellular Therapeutic

Cytori Therapeutics, Inc. announced the launch of its U.S. phase III/pivotal trial to study the efficacy of its ECCS-50 cellular therapeutic in patients with scleroderma associated hand dysfunction. In July 2015, Cytori received follow-on U.S. FDA investigational device approval for recent updates to the Celution® System, which is being used in the STAR trial. The updates include recent technologic advances such as enhanced software code that substantially improves the efficiency of the bedside therapeutic manufacturing process for ECCS-50. Currently three U.S. centers have been initiated. Cytori anticipates that the majority of investigational sites will be active by October 2015. Screening of patients has begun and it is expected that the first U.S. patients will be treated this month. Enrollment duration is expected to be approximately 1 year. STAR is an eighty patient randomized, double blinded controlled trial of a single dose of the ECCS-50 therapeutic compared to placebo. The STAR trial was predicated on promising data from the European phase II/pilot trial named SCLERADEC which was published in 2014 (Granel et al. Annals of Rheumatic Diseases) and reported data suggesting that the treatment was safe and potentially effective in improving certain hand symptoms in patients with scleroderma. Subsequent follow up of the SCLERADEC patients at 12 months revealed that the beneficial effect of Cytori’s ECCS-50 therapy in scleroderma was found to persist beyond 12 months and that data has been accepted for publication and is currently in press.

Cytori Therapeutics Announces U.S. FDA Conditional IDE Approval for Clinical Trial of Technology to Treat Female and Early Male Pattern Baldness

Cytori Therapeutics announced that Kerastem Technologies has received conditional approval from the U.S. Food and Drug Administration's (FDA) Investigational Device Exemption (IDE) to conduct a clinical trial studying the safety and feasibility of its technology for the treatment of female and early male pattern baldness (androgenic alopecia). Kerastem Technologies is a wholly owned subsidiary of Bimini Technologies, which acquired the global and exclusive rights to commercialise Cytori Celution Technology for alopecia and hair related indications from Cytori in 2013. The company stated that the phase II study, called the STYLE trial, follows initial clinical work in Europe and Japan. This clinical experience served as a basis for the U.S. FDA IDE submission. STYLE is a 70 patient controlled trial that is expected to begin enrollment in late 2015 at up to eight centres within the US. The primary endpoint of STYLE trial is safety and tolerability of the treatment and secondary endpoints include change in hair growth and density.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTX:US $0.30 USD -0.0268

CYTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Caladrius Biosciences Inc $1.36 USD +0.085
Cesca Therapeutics Inc $0.63 USD +0.01
International Stem Cell Corp $3.65 USD +0.0001
Nuo Therapeutics Inc $0.06 USD +0.004
StemCells Inc $0.39 USD +0.0055
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 21.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTORI THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at